Strategy Set to Report Q4 Earnings: Buy, Sell or Hold the Stock?
zacks.com
Want to monitor BCAB?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor BCABBioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO! ™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability.